Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies

Michael W Dunne1*, Dan Sahm2 and Sailaja Puttagunta1

Abstract

Background: Dalbavancin is a lipoglycopeptide antibiotic with activity against gram positive pathogens recently approved for treatment of acute bacterial skin and skin structure infections. Pending the introduction of antimicrobial susceptibility tests, we examined the utility of vancomycin inhibitory concentrations to predict dalbavancin susceptibility in a panel of isolates obtained from phase 3 registration studies.

Findings: 99.6% of Staphylococcus aureus and 99.0% of beta-hemolytic streptococci which are susceptible to vancomycin will have an MIC at or below the US FDA susceptibility breakpoint for dalbavancin.

Conclusion: Vancomycin should be considered as a surrogate for in vitro dalbavancin susceptibility testing.

Keywords: Susceptibility testing, Vancomycin, Dalbavancin, Antimicrobial agents, Acute bacterial skin and skin structure infections

With the introduction of new antimicrobial agents comes a need for diagnostic tests available in the community which can confirm the in vitro susceptibility of target pathogens. Those diagnostic tests, however, require a significant amount of research and development and can only be approved once the susceptibility breakpoints for the agent are identified. Consequently, many antibacterial agents newly available for clinical use are not included in the automated testing systems commonly used in hospital settings.

Dalbavancin is a new lipoglycopeptide with activity against Gram-positive pathogens that has a long half-life allowing for infrequent dosing. Based on two phase 3 clinical trials [1] dalbavancin was recently approved in the United States for treatment of acute bacterial skin and skin structure infections (ABSSSI) dosed intravenously as 1000 mg followed one week later by 500 mg [2] (USPI). Antimicrobial susceptibility testing methodologies in broth have been established by the Clinical and Laboratory Standards Institute [3] (CLSI) however commercially available diagnostics are not presently available. In this circumstance, the use of a surrogate agent to assess for in vitro susceptibility is well precedented and has significant utility pending the addition of the new antibacterial agent to an established diagnostic testing susceptibility platform [3,4].

Dalbavancin shares a similar mechanism of action with vancomycin, though providing a significant enhancement in potency, presumably a result of modification to one of the side chains as well as the addition of a lipid tail. The use of vancomycin as a surrogate for dalbavancin in vitro susceptibility has been previously proposed [5], and recently repeated [6] (R.N. Jones, D.J. Farrel, R. K. Flamm, submitted for publication), based on a large collection of isolates obtained from a hospital surveillance program. Recently, in vitro susceptibility data, derived from the DISCOVER clinical development program has also become available that allows for cross tabulation of mean inhibitory concentrations for these two agents.

Findings
Isolates derived from patients enrolled in the dalbavancin clinical development program for ABSSSI were tested for susceptibility against dalbavancin and vancomycin. Identification of isolates was confirmed by MALDI Biotyper
Briefly, dalbavancin was diluted in DMSO and susceptibility testing was performed by broth microdilution in Cation-adjusted Mueller Hinton Broth supplemented with 0.002% (v/v) polysorbate 80, as described in CLSI M7, CLSI M100 and Eurofins Medinet SOP [7] (1-P-PR-PRO-9002355 – Broth Microdilution MIC Testing with Frozen Panels). Quality control and interpretations of results were performed according with CLSI M100 with the reference strains *Staphylococcus aureus* ATCC 29213 and *Streptococcus pneumoniae* ATCC 49619. Vancomycin testing was performed in a similar manner, with differences as outlined in Table 1.

Of the 634 *S. aureus* isolates identified, the dalbavancin MIC \( \text{MIC}_{90} \) was 0.06 μg/ml. Three isolates (0.4%) had an MIC greater than the FDA breakpoint of >0.12 μg/ml. The MIC\( \text{MIC}_{90} \) of *S. aureus* for vancomycin was 1 μg/ml and no isolate had an MIC greater than the breakpoint of 2 μg/ml. Cross tabulation of these susceptibility data confirmed that 99.6% of the isolates that were susceptible to vancomycin were also susceptible to dalbavancin (Table 2).

Of the 192 beta-hemolytic streptococci, which include *S. pyogenes* (87), *S. agalactiae* (36), *S. dysgalactiae* (4), *S. anginosus* group (49), Group C streptococci (9) and Group G streptococci (7), the dalbavancin MIC\( \text{MIC}_{90} \) was 0.06 μg/ml. Two isolates had an MIC >0.12 μg/ml. The two isolates (1%) that would be considered non-susceptible to dalbavancin were both susceptible to vancomycin. Cross tabulation of these susceptibility data confirmed that 99.0% of the isolates that were susceptible to vancomycin were also susceptible to dalbavancin (Table 3).

One patient treated with dalbavancin had an MIC that would be considered non-susceptible (MIC = 0.25 μg/ml). This organism was positive for the Panton-Valentine leukocidin toxin and methicillin resistance and the patient was a clinical success at Day 3 and a clinical cure at Day 14. The other patient with a dalbavancin MIC to *S. aureus* of >0.12 μg/ml (MIC = 0.25 μg/ml) was treated with vancomycin and was a clinical success (Table 4).

### Table 1 CLSI methodology for broth microdilution

| Testing conditions | Dalbavancin | Vancomycin |
|-------------------|-------------|------------|
| **Medium**        | Cation-adjusted Mueller Hinton Broth supplemented with 0.002% (v/v) polysorbate 80 | Cation-adjusted Mueller Hinton Broth |
| **Inoculum**      | Direct colony suspension, equivalent to a 0.5 McFarland standard | Direct colony suspension, equivalent to a 0.5 McFarland standard |
| **Incubation**    | 35 +/- 2°C; ambient air; 24 hours | 35 +/- 2°C; ambient air; 24 hours |
| **Solvent/diluent** | DMSO | Water |

### Table 2 Cross tabulation of *S. aureus* isolates with mean inhibitory concentrations for vancomycin and dalbavancin

| Vancomycin MIC (μg/ml) | Dalbavancin MIC (μg/ml) | 0.008 | 0.015 | 0.03 | 0.06 | 0.12 | 0.25 |
|------------------------|-------------------------|-------|-------|-----|------|------|------|
| 0.25                   |                         | 1     |       |     |      |      |      |
| 0.5                    |                         | 3     | 142   | 191 | 5    | 1    |      |
| 1                      |                         | 1     | 2     | 49  | 230  | 7    | 1    |
| 2                      |                         |       |       |     |      |      | 1    |

### Table 3 Cross tabulation of Beta-hemolytic streptococcal isolates with mean inhibitory concentrations for vancomycin and dalbavancin

| Vancomycin MIC (μg/ml) | Dalbavancin MIC (μg/ml) |
|------------------------|-------------------------|
| 0.001                  | 1                       |
| 0.002                  | 1                       |
| 0.004                  | 1                       |
| 0.008                  | 1                       |
| 0.015                  | 3                       |
| 0.03                   | 4                       |
| 0.06                   | 1                       |
| 0.12                   | 1                       |
| 0.25                   | 2                       |
| 0.5                    | 19                      |
| 1                      | 16                      |
| 2                      | 4                       |

### Table 4 Two patients with *S. aureus* isolates with a dalbavancin MIC of 0.25 μg/ml

| Characteristic | Patient 1 | Patient 2 |
|---------------|-----------|-----------|
| Treatment Group | Vancomycin/linezolid | Dalbavancin |
| Age (years)   | 51        | 34        |
| Type of infection | Traumatic Wound Infection | Cellulitis |
| Wound culture | MSSA | MRSA |
| Vancomycin MIC | 1 | 0.5 |
| PVL toxin    | Negative | Positive |
| mecA gene    | Negative | Positive |
| Clinical response at 48–72 hours | Responder | Responder |
| Clinical outcome at Day 14 | Success | Success |
vancomycin > 2 μg/ml. Anecdotally, a small number of these patients have been observed in clinical trials and have been successfully treated. While the FDA breakpoint is 0.12 μg/ml, based to a large degree on the clinical outcome data of a sufficient number of patients infected with isolates at that MIC, a preliminary assessment of the ECOFF calculations [9] for S. aureus suggests a breakpoint of 0.25 μg/mL, as this is the highest MIC of organisms lacking phenotypically expressed resistance [10]. A reassessment of the existing breakpoint will be enabled by analysis of more patients treated with dalbavancin who had organisms with an MIC > 0.12 μg/ml.

A strong correlation between vancomycin and dalbavancin in vitro susceptibility results was observed for both sets of isolates. While broth microdilution methodologies to guide performance of in vitro susceptibility testing have been published, these data support the proposal that vancomycin can be used as a surrogate for susceptibility testing of dalbavancin, pending the introduction of dalbavancin into established diagnostic susceptibility testing platforms.

Over 99.6% of S. aureus and 99.0% of beta-hemolytic streptococci which are susceptible to vancomycin (MIC ≤ 2 μg/mL) will have an MIC at or below the USA susceptibility breakpoint for dalbavancin. Vancomycin should be considered for use as a surrogate for in vitro dalbavancin susceptibility testing.

Availability of supporting data
The data supporting the results of this study are included within this article.

Competing interests
Dr. Dunne is an employee of Actavis plc and was the Chief Medical Officer of Durata Therapeutics, Inc. Dr. Puttagunta is an employee of Actavis plc and was the VP of Development and Clinical Affairs at Durata Therapeutics, Inc. Dr. Sahm has nothing to disclose.

Authors’ contributions
MWD and SP made substantial contributions to the acquisition of data and the analysis plan. MWD, SP and DS made substantial contributions to the analysis and interpretation of the data. MWD and SP were involved in drafting the manuscript. All authors have read and approved the final manuscript.

Acknowledgements
The authors appreciate the careful review of this manuscript by Sandra McCurdy and the administrative assistance of Shaina Barnes.

Author details
1Durata Therapeutics, Inc., Branford, CT, Branford, CT, USA. 2International Health Care Associates, Inc, Washington, DC, USA.

Received: 15 December 2014 Accepted: 23 March 2015
Published online: 02 April 2015

References
1. Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. NEJM. 2014;370(23):2169–78.

2. DalvanceTM Package Insert 2014. DurataTherapeutics Intl., Chicago, IL, USA. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021883s000lbl.pdf. Accessed July 2014
3. Clinical and Laboratory Standards Institute. M100-S24. Performance standards for antimicrobial susceptibility testing: 24th informational supplement. Wayne, PA: CLSI; 2014.
4. Friedland IR, Isaacs R, Mixson LA, Mioty M, Woods GL. Use of surrogate antimicrobial agents to predict susceptibility to ertapenem. Diagn Microbiol Infect Dis. 2002;43:61–4.
5. Jones RN, Sader HS, Fritsche TR, Hogan PA, Sheehan DJ. Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program. J Clin Microbiol. 2006;44:2622–5.
6. Jones RN, Farrell DJ, Flammm RK, Sader HS, Dunne MW, Mendes RE. Surrogate Analysis of Vancomycin to Predict Susceptible Categorization of Dalbavancin. Diagn Microbiol Infect Dis. 2015 Published online Feb 7. doi:10.1016/j.diagmicrobio.2015.01.017.
7. CLSI M100-S24. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement. 2014, 34: 1.
8. Jones RN, Sader HS, Flammm RK. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). 2013;75:304–7.
9. Kahlmeter G, Kahlmeter G, Myhre E, Galas MF. A new method for normalized interpretation of antimicrobial resistance from disk test results for comparative purposes. Clin Microbiol Infect. 2003;9:120–32.
10. Kahlmeter G, EUCAST. ECOFF presentation to clinical laboratory and standards institute meeting. Tampa, FL USA: EUCAST; 2013.